Active Stocks Momentum: AbbVie Inc (ABBV), Regions Financial Corp (RF)


AbbVie Inc (NYSE:ABBV)

Stock’s Trading Stats:

AbbVie Inc (NYSE:ABBV) is trading up with a percentage change of 1.26% and is at $59.26 right now. The Company’s market capitalization stands at $95.88 Billion in the current trading Session whereas, its outstanding shares are 1.62 Billion.

Recent Press Release:

AbbVie Inc. (ABBV) on April 11, 2016 declared the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Venclexta (venetoclax) tablets for patients diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one preceding therapy. The FDA approved this indication under accelerated approval based on overall response rate, and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. The FDA approved Venclexta as a first-in-class, oral, once-daily medicine1 that selectively inhibits the BCL-2 protein.1 The BCL-2 protein blocks apoptosis (programmed cell death) of cells, counting some cancer cells, and can be overexpressed in CLL cells.1 Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It is marketed collaboratively by the companies in the U.S. and by AbbVie outside of the U.S.

The safety of single agent Venclexta is based on pooled data of 240 patients with formerly treated CLL from two Phase 2 trials and one Phase 1 trial. The most common adverse reactions (≥20%) were neutropenia (low white blood cell count), diarrhea, nausea, low red blood cell count, upper respiratory tract infection, thrombocytopenia (low platelet count) and fatigue. Serious adverse reactions were stated in 43.8 percent of patients. The most frequent serious adverse reactions (≥2%) were pneumonia, low white blood cell count with fever (febrile neutropenia), fever, abnormal breakdown of red blood cells resulting in low red blood cell count (autoimmune hemolytic anemia (AIHA)), low red blood cell count, and tumor lysis syndrome (TLS). Discontinuations due to adverse reactions occurred in 8.3 percent of patients. The most frequent adverse reactions leading to drug discontinuation were thrombocytopenia and AIHA. Dosage adjustments due to adverse reactions occurred in 9.6 percent of patients. The most frequent adverse reactions leading to dose adjustments were neutropenia, febrile neutropenia, and thrombocytopenia. Tumor lysis syndrome (TLS) is an important, identified risk when initiating Venclexta.

Regions Financial Corp (NYSE:RF)

Stock’s Trading Stats:

Regions Financial Corp (NYSE:RF) is surging 1.93% percent and is at $7.91 in the Real-Time trading session. The stock’s market capitalization stands at $10.22 Billion with outstanding shares of 1.28 Billion.

Recent Press Release:

Regions Financial Corporation (RF) on April 8, 2016 declared a contract to offer a streamlined online consumer loan application and underwriting experience for Regions Bank customers. The unique agreement will combine Regions’ established banking and online presence at with Avant’s technology platform to provide a fast, convenient digital experience for customers seeking consumer loans.

The Regions/Avant co-branded loan application process will be made accessible during the second half of 2016. Customers may apply for an unsecured personal loan through the AvantPlatform on the Regions website — Applicants are assessed and receive an immediate credit decision, followed by automated verification steps for final approval. Loans sizes range from $1,000-$35,000 and many applicants may have access to funds as soon as the next business day.